Cyclerion Therapeutics (CYCN) Competitors $2.46 -0.09 (-3.53%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.44 -0.02 (-0.81%) As of 09/12/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCN vs. MAAQ, THAR, RVPH, RNTX, ITRM, KZR, ASBP, PMN, CASI, and CLSDShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Mana Capital Acquisition (MAAQ), Tharimmune (THAR), Reviva Pharmaceuticals (RVPH), Rein Therapeutics (RNTX), Iterum Therapeutics (ITRM), Kezar Life Sciences (KZR), Aspire Biopharma (ASBP), Promis Neurosciences (PMN), CASI Pharmaceuticals (CASI), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. Its Competitors Mana Capital Acquisition Tharimmune Reviva Pharmaceuticals Rein Therapeutics Iterum Therapeutics Kezar Life Sciences Aspire Biopharma Promis Neurosciences CASI Pharmaceuticals Clearside Biomedical Mana Capital Acquisition (NASDAQ:MAAQ) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends. Is MAAQ or CYCN more profitable? Mana Capital Acquisition has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -89.51%. Mana Capital Acquisition's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mana Capital AcquisitionN/A N/A N/A Cyclerion Therapeutics -89.51%-22.63%-20.65% Do insiders & institutionals hold more shares of MAAQ or CYCN? 68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 34.3% of Cyclerion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has preferable valuation and earnings, MAAQ or CYCN? Mana Capital Acquisition has higher earnings, but lower revenue than Cyclerion Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMana Capital AcquisitionN/AN/AN/AN/AN/ACyclerion Therapeutics$2.17M3.78-$3.06M-$0.74-3.32 Does the media favor MAAQ or CYCN? In the previous week, Cyclerion Therapeutics had 2 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 2 mentions for Cyclerion Therapeutics and 0 mentions for Mana Capital Acquisition. Cyclerion Therapeutics' average media sentiment score of 0.45 beat Mana Capital Acquisition's score of 0.00 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Mana Capital Acquisition Neutral Cyclerion Therapeutics Neutral SummaryCyclerion Therapeutics beats Mana Capital Acquisition on 5 of the 8 factors compared between the two stocks. Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.51M$3.20B$5.86B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-3.3221.1774.8625.97Price / Sales3.78436.36517.37181.73Price / CashN/A46.6837.5660.44Price / Book0.759.6112.156.29Net Income-$3.06M-$53.29M$3.29B$270.96M7 Day Performance10.31%0.13%0.73%3.85%1 Month Performance0.57%5.61%4.82%4.85%1 Year Performance-12.77%10.49%60.57%26.11% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics1.5419 of 5 stars$2.46-3.5%N/A-22.2%$8.51M$2.17M-3.3230Short Interest ↑MAAQMana Capital AcquisitionN/A$3.81+0.5%N/A+1,192.7%$30.96MN/A0.001THARTharimmune2.4666 of 5 stars$5.43-8.7%$17.00+213.1%+5.0%$30.93MN/A-0.892Short Interest ↑Gap UpRVPHReviva Pharmaceuticals3.0018 of 5 stars$0.45+0.7%$5.20+1,047.9%-60.5%$30.80MN/A-0.705RNTXRein Therapeutics0.999 of 5 stars$1.30-6.5%N/AN/A$30.30MN/A-0.489News CoveragePositive NewsGap UpHigh Trading VolumeITRMIterum Therapeutics2.8587 of 5 stars$0.66-3.2%$9.00+1,274.0%-38.5%$29.30MN/A-0.7710Positive NewsShort Interest ↓KZRKezar Life Sciences3.8406 of 5 stars$3.89-1.6%$9.00+131.6%-30.3%$28.45M$7M-0.4060Positive NewsAnalyst UpgradeASBPAspire BiopharmaN/A$0.56-2.9%N/AN/A$27.66MN/A0.00N/APositive NewsPMNPromis Neurosciences3.6823 of 5 stars$0.53-2.2%$4.33+720.7%-64.8%$27.51MN/A-2.535Positive NewsShort Interest ↓CASICASI Pharmaceuticals3.778 of 5 stars$2.22-3.9%$4.00+80.2%-68.4%$27.49M$28.54M-0.77180CLSDClearside Biomedical2.3675 of 5 stars$0.35-4.8%$4.20+1,100.0%-76.3%$27.48M$1.66M-0.9530Stock SplitGap Down Related Companies and Tools Related Companies MAAQ Competitors THAR Competitors RVPH Competitors RNTX Competitors ITRM Competitors KZR Competitors ASBP Competitors PMN Competitors CASI Competitors CLSD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCN) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYCN Stock Alerts